Strides continues to deliver exceptional performance with highest ever quarterly EBITDA of Rs.2 359 million in Q3 FY26
Strides Pharma Science: Announcement under Regulation 30 (LODR)-Press Release / Media Release
January 30, 2026
Download PDF
Strides Pharma